GlassScriptPhysician profile
Renu Tamirisa
NPI 1336149400
$4,712.11
in general payments reported to CMS, 2019-2025
33 companies · $586 in 2025
The $586 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $531 · 2020: $548 · 2021: $465 · 2022: $1,011 · 2023: $819 · 2024: $752 · 2025: $586.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,157.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,157.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $749.68 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $500.17 | 2020-2025 | Repatha, Evenity, Otezla |
| Horizon Therapeutics Plc | $484.33 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $416.36 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $390.41 | 2019-2025 | Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $281.56 | 2021-2025 | |
| Abbvie INC. | $161.69 | 2021-2025 | Ubrelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $145.23 | 2022-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $136.53 | 2019 | |
| Astellas Pharma US INC | $131.89 | 2019-2024 | Veozah |
| Mylan Specialty L.P. | $125.00 | 2019 | |
| Galderma Laboratories, L.P. | $117.94 | 2019-2024 | |
| Edwards Lifesciences Corporation | $102.88 | 2020 | |
| Exact Sciences Corporation | $95.80 | 2023-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $94.04 | 2023-2025 | Freestyle Libre 3 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $88.91 | 2021-2024 | Dexcom G6 Transmitter |
| Kowa Pharmaceuticals America, INC. | $88.90 | 2021-2023 | Seglentis, Livalo |
| Glaxosmithkline, LLC. | $86.10 | 2019-2024 | Arexvy |
| Novartis Pharmaceuticals Corporation | $83.43 | 2022-2024 | |
| Amarin Pharma, INC. | $58.85 | 2019-2022 | |
| Esperion Therapeutics, INC. | $43.09 | 2021-2025 | Nexletol |
| Pfizer INC. | $38.56 | 2023 | |
| Medtronic, INC. | $36.13 | 2022-2025 | Intellis Adaptivestim |
| Optinose US, INC. | $34.60 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $33.75 | 2024 | Voquezna |
| Sumitomo Pharma America, INC. | $31.65 | 2025 | Gemtesa |
| Biohaven Pharmaceutical Holding Company LTD. | $30.64 | 2022 | |
| Genentech USA, INC. | $29.66 | 2020 | |
| Allergan, INC. | $29.52 | 2020 | |
| Sanofi-Aventis U.S. LLC | $18.12 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $17.75 | 2024 | Rexulti |
| Azurity Pharmaceuticals, INC. | $14.59 | 2023 | Adthyza |
| Viatris Specialty LLC | $14.35 | 2025 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Renu Tamirisa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.